

PRECISION ONCOLOGY FORUM

6-7 OCTOBER 2020 HYATT REGENCY NEW BRUNSWICK USA

DAY 1

7:30am – 8:00am	Coffee and Registration
8:00am – 8:05am	Welcome and Introduction by Chair
8:05am – 8:45am	Plenary Keynote
8:45am – 9:30am	Opening plenary panel discussion Current Roadblocks to delivering precision oncology care at a scale. Discussion Points - Slow adoption of lab tests Reimbursement Challenges Delayed testing Complicated test reports – and getting more complicated (i.e., MSI, TMB, immunoscores) Physician/Patient Education (3 speakers all give elevator pitch/landscape 6/7 minutes and reconvene on a panel discussion)
9:30am – 10:20am	Road to Precision - early days in CAR-T's evolution but huge promise for future oncology landscape. Discussion Points - Solid Tumor Developments Resistance mechanisms Rise of CAR NK
10:20am – 10:50am	Coffee Break
10:50am – 11:40am	Epigenomics and Immunotherapy - A potential precision partnership in the fight against cancer. Discussion Points - This session will discuss the role of the Cancer Epigenome and how it can be harnessed to trigger the Immune system to fight tumorigenesis and drug resistance. ICB Therapy and current limitations/potential for future therapeutic combinations. Going beyond Hematological Malignancies - Epigenetics role in precision oncology. Methylation array profiling in glioblastoma and other solid tumors.

PRECISION ONCOLOGY FORUM

6-7 OCTOBER 2020 HYATT REGENCY NEW BRUNSWICK USA

11:40am – 12:30pm

Precision Medicine for Breast Cancer needs precise guidelines - Time for an overhaul?

Discussion Points -

Discuss - who do we test, when do we test how do we test.?

Current Guidelines are confusing and Complex

Need for Expansion of indications for comprehensive genetic testing in patients with breast cancer.

12:30pm – 1:30pm

Lunch

Afternoon Sessions

1:30pm – 2:15pm

When will PGx oncology testing hit a home run? Still too many regulatory curve balls?

Discussion Points -

the availability of PGx tests at an affordable cost and in a timely manner;

the standardization of PGx testing and reporting;

educational opportunities to improve the understanding of which test to order, when to order tests and how to interpret the results;\

Mitigation of polypharmacy

Access to EMR systems providing CDS and to guidelines for PGx-informed prescription;

evidence of clinical utility and cost-effectiveness applicable to the pertinent clinical setting.

2:15pm – 3:05pm

RWE and RCT's - Replication or Integration?

Discussion Points -

Expanding Indications for Approved Drugs

Role of EHR based RWE generation in oncology

Complementary Strategies for broadening population groups

New approaches on blended Hybrid Controls

Future Opportunities in RWD for drug development

FDA Framework

3:05pm – 3:55pm

A New Generation of Precision Oncology - Building homogenous patient populations through more refined use of Biomarkers, Omics Data, AI and Machine Learning.

Discussion Points -

How do we integrate multiple molecular modalities: genomics, transcriptomics, epigenomics, immune profiling, proteomics, etc to predict the best treatment option?

Will AI/ML solve the temporal and spatial data deluge that's coming?

New in vivo and in silico models to deliver on the precision promise Organoids, fruit flies, zebrafish - is this a viable path?

3:55pm – 4:25pm

Coffee Break

PRECISION ONCOLOGY FORUM

6-7 OCTOBER 2020 HYATT REGENCY NEW BRUNSWICK USA

4:25pm – 5:10pm

Augmenting the role of the Pathologist with AI to drive precision oncology
Discussion Points -
Discuss uses of ML,DL and AI with differentiating benign and malignant tumors
Compare Academic and community settings - progress respectively.
Improved diagnostic /decision support workflow.
Fundamental Change is occurring in how tissue is processed and workflow standardised.
Building predictive systems by detecting prognostic features - obviate need for expensive and time consuming molecular assays.
Build tools to search large datasets to look for images with no annotation or labels.

5:10pm – 6:10pm

Roundtables

Roundtables are sponsored and moderated by a subject leader with domain expertise on a particular topic. Specific themes for discussion will be added to the agenda as they evolve.

1. Gene Fusions
2. Neuro-Oncology - a promising future?
3. NGS for Pediatric Oncology
4. Liquid Biopsy - Current Impact in Clinical Care
5. Single Cell Sequencing and its role in Precision Oncology
6. Electronic Patient Reported Outcomes
7. Digital Therapeutics in the field of Oncology
8. Can Machine Learning guide insights from Cross-talk genetic screening (Germline and Somatic) combined with complex multi omic datasets to deliver more predictive cancer care?
9. Cancer Vaccines - a promising Future?
10. Mining the Data Lakes - Scanning the depths for targeted cancer biomarker signals

6:30pm – 8:30pm

Drinks and Networking Reception

PRECISION ONCOLOGY FORUM

6-7 OCTOBER 2020 HYATT REGENCY NEW BRUNSWICK USA

DAY 2

8:00am – 8:45am	Keynote
8:45am – 9:45am	<p>A new decision maker on the team - the rise of the VMTB</p> <p>Discussion Points -</p> <p>How do we capture and create a learning system from MTB discussions and recommendations? i.e, capture treatment rationales</p> <p>Are oncologists open to a virtual model ?</p> <p>An answer to current Clinical Trial enrollment limitations?</p>
9:45am – 10:30am	Coffee Break
10:30am – 11:00am	Baskets, Umbrellas and AI -- new trial designs for an era of Precision Oncology'
11:00am – 11:45am	<p>This session will discuss the challenges and issues that still pervade clinical trial design and patient recruitment and how technologies and novel regulatory oversight can mitigate some of the issues around complexity and cost of current oncology trials.</p>
11:45am – 12:30pm	<p>How to build a comprehensive and equitable pediatric precision oncology program.</p> <p>Discussion Points -</p> <p>Examples of pediatric oncology programs.</p> <p>Disparities and solutions.</p> <p>Use of NGS.</p>
12:30pm – 1:30pm	Lunch
1:30pm – 2:45pm	<p>Patient Fireside Chat</p> <p>Cognitive Dissonance - time to fix Lymphedema.</p> <p>We discuss the issues affecting millions of cancer survivors who live with this debilitating disease and discuss current thinking on therapeutic opportunities and address the preventative measures that can stop this disease in its tracks.</p>

PRECISION ONCOLOGY FORUM

6-7 OCTOBER 2020 HYATT REGENCY NEW BRUNSWICK USA

DAY 2

2:45pm – 3:35pm

No Precision without Inclusion - fixing health disparities with data diversity.

Discussion Points -

Understanding Patient and Tumor.

The need for inclusion in Human Tissue Biobanks.

Discuss the current issues around cancer mortality and inadequate/inequitable treatment in indigenous and minority populations.

3:35pm – 4:00pm

Primum Non Nocere - Precision Oncology depends on Precision Dosing

Discussion points -

Oncology field lacks the infrastructure needed for routine therapeutic drug monitoring.

Need for target ranges for dose exposure to be established, laboratory developed tests to measure plasma drug concentrations.

Monitoring Training for oncologists logistical and timing implications as when to collect plasma samples.

No incentives for industry to target the concentration range - marketing headache/overly complicated.

Patient driven movement in motion - examples.

4:00pm

Conference Close